AACR Annual Meeting 2023
Orange County Convention Center, Orlando, FloridaApril 14, 2023 - April 19, 2023
The AACR Annual Meeting highlighted the best cancer science and medicine from institutions all over the world. Attendees were invited to stretch their boundaries, form collaborations, attend sessions outside their own areas of expertise, and learn how to apply exciting new concepts, tools, and techniques to their own research. Check out our poster and presentation from the event and explore our products and resources below to see how we can support cancer diagnostics and drug development.
Did you miss us at booth #1633 and would like to speak to one of ATCC’s representatives about a product or service? Contact us so we can discuss your needs.
Check Out Our Exhibitor Spotlight Theater
Cell-based Models for the Discovery and Development of Cancer Therapeutics
Check out our presentation to learn about our portfolio of 2-D and 3-D models from the Human Cancer Models Initiative (HCMI) consortium and our new immuno-oncology reporter models for accelerating your oncology drug discovery and development.
Presenters: Utsav Sharma, PhD, Product Manager, Oncology, ATCC; Hyeyoun Chang, PhD, Scientist, ATCC; James Clinton, PhD, Lead Scientist, ATCC
Date: April 18, 2023
Time: 12:30 PM – 1:30 PM
Location: Spotlight Theater D
Watch Our Poster Session
Immune Checkpoint Reporter Cell Lines Based on the Protein Profiling of ATCC Cell Lines for Cancer Immunotherapy Drug Screening
Watch our poster session to learn about the development of immune checkpoint reporter cell lines and their application in immunotherapy drug screening.
Presenter: Hyeyoun Chang, PhD, Scientist, ATCC
Date: April 19, 2023
Time: 9:00 AM – 12:30 PM
Location: Section 38
Poster Board Number: 15
Abstract Presentation Number: 6643
Human Cancer Models Initiative
ATCC is collaborating with the Human Cancer Models Initiative (HCMI) to offer scientists a wide variety of next-generation 2-D and 3-D patient-derived in vitro cancer models, including organoids.
ATCC is committed to making available a growing collection of models generated by the HCMI, which will include both common as well as rare and understudied examples of cancer from numerous tissues. These HCMI models are valuable tools to study cancer, identify and target novel therapies, and facilitate translational cancer research.Find next-generation models
Download a PDF of our literature
ATCC provides a large collection of fully characterized and authenticated cell lines, human primary cells, and advanced cell models such as checkpoint luciferase reporter cells and CAR-T target luciferase reporter cells that support immuno-oncology therapeutic development.More
CAR-T Target Luciferase Reporter Cells
ATCC generated CAR-T Target Luciferase Reporter Cells lines that have high endogenous expression of clinically relevant cell surface tumor antigens, such as CD19, CD20, and HER2. These new immuno-oncology tools are comprised of both solid and liquid tumor cell lines that exhibit sensitive and stable luciferase reporter expression.More
Cell Lines by Gene Mutation
This guide organizes our ATCC tumor cell lines according to gene of interest and provides information for each line about the specific mutation.More
Genetic Alteration Cell Panel
A comprehensive guide providing details and data on our AKT, BRAF, EGFR, ERK, FGFR, MET, MYC, PI3K, PTEN, and RAS genetic alteration cell panels.More
Isogenic Cell Lines
With genome editing tools such as CRISPR/Cas9, ATCC has created isogenic cell lines with mutants of key oncogenes, which are ideal for identifying novel, personalized treatment regimens. Explore our resources.More
THP-1 Reporter Cells
ATCC introduced luciferase reporters containing the response element of immunologically important transcription factors into the THP-1 cell line. The THP-1 LUC2 cell lines provide a means to confidently measure immune modulation for all your drug discovery and development efforts.More
ATCC Tumor Cell Panels by Gene Mutations and Tissue Origin
The value of tumor cell lines, as research models and drug discovery tools, is greatly enhanced when there is an understanding of the underlying genetic abnormalities that drive their phenotype. ATCC has taken the first step for your research by annotating our tumor cell lines with gene mutation data from the Sanger Institute COSMIC database, and additional in-house testing.More
Tumor/Normal Matched Cell Line Pairs
Tumor-derived cell lines matched to either normal or metastatic cell lines obtained from the same patient provide a valuable resource for cancer studies.More
Contact us today
Your ATCC sales representative stands ready to discuss your research needs and provide you with personalized care. Please complete our form to let us know how we can help, and we will start working on your needs right away.